Home
COYA
COYA News

Latest Coya Therapeutics Inc. (COYA) News on February 22, 2025

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Benzinga

16 days ago

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Business Wire

16 days ago

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Business Wire

18 days ago

Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

Pharma Voice

a month ago

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

Business Wire

a month ago

Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

Benzinga

a month ago

EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases

Business Wire

2 months ago

Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD)

Business Wire

3 months ago

Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference

Business Wire

3 months ago

Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Business Wire

4 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results

MT Newswires

4 months ago

Coya Therapeutics New CEO Arun Swaminathan Takes Helm

Business Wire

4 months ago

Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer

Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results

TipRanks

4 months ago

Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results

MT Newswires

4 months ago

Sector Update: Health Care Stocks Ease Late Afternoon

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

Benzinga

4 months ago

Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study

MT Newswires

4 months ago

Coya Therapeutics Shares Fall After Phase 2 Alzheimer's Disease Study Results

Business Wire

4 months ago

Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)

Business Wire

4 months ago

Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease

Business Wire

4 months ago

Coya Therapeutics Announces Closing of $10.0 Million Private Placement

Business Wire

4 months ago

Coya Therapeutics Announces $10.0 Million Private Placement

Business Wire

4 months ago

Coya Therapeutics Chairman and CEO Howard Berman Selected for PharmaVoice 100

Business Wire

5 months ago

Coya Therapeutics to Participate in Fireside Chat at the Chardan 8th Annual Genetic Medicines Conference

Business Wire

5 months ago

Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Simply Wall St.

6 months ago

Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation

Business Wire

6 months ago

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Business Wire

6 months ago

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Business Wire

6 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results

Business Wire

7 months ago

Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid

Business Wire

7 months ago

Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Business Wire

8 months ago

Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with Funding from the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform into the Clinic

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Business Wire

8 months ago

Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology

Business Wire

9 months ago

Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology

Business Wire

9 months ago

Coya Therapeutics Announces Inclusion in the MSCI USA Micro Cap Index

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Benzinga

9 months ago

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases

Coya Therapeutics concludes Phase II Alzheimer’s therapy trial

Clinical Trials Arena

9 months ago

Coya Therapeutics concludes Phase II Alzheimer’s therapy trial

Business Wire

9 months ago

Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease

MT Newswires

9 months ago

Coya Therapeutics Receives $5 Million Equity Investment from Alzheimer's Drug Discovery Foundation

Business Wire

9 months ago

Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)

Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%

Simply Wall St.

9 months ago

Coya Therapeutics, Inc.'s (NASDAQ:COYA) largest shareholders are retail investors with 60% ownership, insiders own 16%

GuruFocus.com

9 months ago

Coya Therapeutics Reports First Quarter 2024 Financial Results

Business Wire

9 months ago

Coya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial Results

Business Wire

10 months ago

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

Business Wire

10 months ago

Coya Therapeutics to Participate in the Mizuho Neuroscience Summit

Business Wire

10 months ago

Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit

Business Wire

10 months ago

Coya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate

Simply Wall St.

a year ago

We're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn Rate

GuruFocus.com

a year ago

Coya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate Updates

Business Wire

a year ago

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Business Wire

a year ago

Coya Therapeutics to Participate in BTIG Fireside Discussion

Business Wire

a year ago

Coya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology Conference

Business Wire

a year ago

Coya Therapeutics Presents Biomarker Data on Neuroinflammatory Pathways in Frontotemporal Dementia (FTD) at the AD/PD 2024 Conference

Business Wire

a year ago

Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 Conference

Business Wire

a year ago

Coya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology Conference

Business Wire

a year ago

Coya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"

Business Wire

a year ago

Coya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory Diseases

MiX Telematics Reports Third Quarter Fiscal Year 2024 U.S. GAAP Financial Results

Business Wire

a year ago

MiX Telematics Reports Third Quarter Fiscal Year 2024 U.S. GAAP Financial Results

New Pacific Metals Announces 2024 Plans for Operations in Bolivia

PR Newswire

a year ago

New Pacific Metals Announces 2024 Plans for Operations in Bolivia

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Zacks

a year ago

Are Medical Stocks Lagging AlloVir (ALVR) This Year?

Business Wire

a year ago

Coya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology Conference

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

GlobeNewswire

a year ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Phunware Appoints Industry Veteran Elliot Han to its Board of Directors

GlobeNewswire

a year ago

Phunware Appoints Industry Veteran Elliot Han to its Board of Directors

NaaS Technology's Full Portfolio of Charging Pile Products Obtained CE Certification from the European Union

PR Newswire

a year ago

NaaS Technology's Full Portfolio of Charging Pile Products Obtained CE Certification from the European Union

Why QuickLogic (QUIK) Outpaced the Stock Market Today

Zacks

a year ago

Why QuickLogic (QUIK) Outpaced the Stock Market Today

Standard Lithium Advances South West Arkansas Project: Definitive Feasibility Study and Front-End Engineering Design Firm Chosen

GlobeNewswire

a year ago

Standard Lithium Advances South West Arkansas Project: Definitive Feasibility Study and Front-End Engineering Design Firm Chosen

Stewart Elected to Serve on the Head Office Board of Directors for the Federal Reserve Bank of San Francisco

GlobeNewswire

a year ago

Stewart Elected to Serve on the Head Office Board of Directors for the Federal Reserve Bank of San Francisco

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

PR Newswire

a year ago

Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

Business Wire

a year ago

Coya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call Series

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?

Zacks

a year ago

Has Leidos (LDOS) Outpaced Other Aerospace Stocks This Year?

Business Wire

a year ago

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

PR Newswire

a year ago

DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Simply Wall St.

a year ago

IO Biotech, Inc. (NASDAQ:IOBT) most popular amongst private equity firms who own 61% of the shares, institutions hold 24%

Built In Honors Terran Orbital in Its Esteemed 2024 Best Places To Work Awards

Business Wire

a year ago

Built In Honors Terran Orbital in Its Esteemed 2024 Best Places To Work Awards

Valens Semiconductor and Intel Foundry Services Announce Strategic Relationship for Next Generation A-PHY Product

PR Newswire

a year ago

Valens Semiconductor and Intel Foundry Services Announce Strategic Relationship for Next Generation A-PHY Product

Business Wire

a year ago

Coya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Business Wire

a year ago

MFS Announces Closed-End Fund Distributions

H World Group Limited Announces the Change of Officers

GlobeNewswire

a year ago

H World Group Limited Announces the Change of Officers

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND ANNOUNCES MONTHLY DISTRIBUTION

PR Newswire

a year ago

NEUBERGER BERMAN REAL ESTATE SECURITIES INCOME FUND ANNOUNCES MONTHLY DISTRIBUTION

Syntec Optics Launches Innovative Thermal Clip-On Scope (Nasdaq: OPTX)

GlobeNewswire

a year ago

Syntec Optics Launches Innovative Thermal Clip-On Scope (Nasdaq: OPTX)

Business Wire

a year ago

Mr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.

While hedge funds own 29% of Sound Financial Bancorp, Inc. (NASDAQ:SFBC), retail investors are its largest shareholders with 41% ownership

Simply Wall St.

a year ago

While hedge funds own 29% of Sound Financial Bancorp, Inc. (NASDAQ:SFBC), retail investors are its largest shareholders with 41% ownership

IX Acquisition Corp. Announces Shareholder Meeting Results and New Monthly Contribution to be Deposited into Trust Account

GlobeNewswire

a year ago

IX Acquisition Corp. Announces Shareholder Meeting Results and New Monthly Contribution to be Deposited into Trust Account

David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfolio

GuruFocus.com

a year ago

David Einhorn's Greenlight Capital Adds Coya Therapeutics to Its Portfolio

David Einhorn's Greenlight Capital Boosts Coya Therapeutics Holding

GuruFocus.com

a year ago

David Einhorn's Greenlight Capital Boosts Coya Therapeutics Holding

12 Best Micro-Cap Dividend Stocks To Buy Now

Insider Monkey

a year ago

12 Best Micro-Cap Dividend Stocks To Buy Now

AGS Partners With Three Rivers Resort to Deliver An AGS-Exclusive Table Games Floor

GlobeNewswire

a year ago

AGS Partners With Three Rivers Resort to Deliver An AGS-Exclusive Table Games Floor

3 Meme Stocks I Wouldn’t Touch With a 10-Foot Pole

InvestorPlace

a year ago

3 Meme Stocks I Wouldn’t Touch With a 10-Foot Pole

New Strong Buy Stocks for December 8th

Zacks

a year ago

New Strong Buy Stocks for December 8th

G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%

Simply Wall St.

a year ago

G1 Therapeutics (NASDAQ:GTHX) adds US$67m to market cap in the past 7 days, though investors from five years ago are still down 90%

Charles Rowland Bought 179% More Shares In Generation Bio

Simply Wall St.

a year ago

Charles Rowland Bought 179% More Shares In Generation Bio

AdTheorent Health Audiences, Powered by HABi™, Earn Neutronian's NQI Certification for Data Quality, Privacy and Transparency

PR Newswire

a year ago

AdTheorent Health Audiences, Powered by HABi™, Earn Neutronian's NQI Certification for Data Quality, Privacy and Transparency

WESTERN COPPER AND GOLD PROVIDES UPDATE ON THE PORT OF SKAGWAY

CNW Group

a year ago

WESTERN COPPER AND GOLD PROVIDES UPDATE ON THE PORT OF SKAGWAY

CorMedix Inc. Announces Partnership With The Leapfrog Group

GlobeNewswire

a year ago

CorMedix Inc. Announces Partnership With The Leapfrog Group

XAI Octagon Floating Rate & Alternative Income Term Trust Declares its Monthly Common Shares Distribution of $0.085 per Share

Business Wire

a year ago

XAI Octagon Floating Rate & Alternative Income Term Trust Declares its Monthly Common Shares Distribution of $0.085 per Share

GlobeNewswire

a year ago

AdTheorent to Present at NobleCon 19

Satellogic Inc.'s (NASDAQ:SATL) market cap surged US$12m last week, private companies who have a lot riding on the company were rewarded

Simply Wall St.

a year ago

Satellogic Inc.'s (NASDAQ:SATL) market cap surged US$12m last week, private companies who have a lot riding on the company were rewarded

Mynaric Secures Another Contract with a U.S. Customer for its CONDOR Mk3 Terminals

ACCESSWIRE

a year ago

Mynaric Secures Another Contract with a U.S. Customer for its CONDOR Mk3 Terminals

WESTERN COPPER AND GOLD ANNOUNCES FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO

PR Newswire

a year ago

WESTERN COPPER AND GOLD ANNOUNCES FURTHER INVESTMENT AND ENTRY INTO A NEW INVESTOR RIGHTS AGREEMENT WITH RIO TINTO

Silvercrest Asset Management Group Inc. (NASDAQ:SAMG) is a favorite amongst institutional investors who own 64%

Simply Wall St.

a year ago

Silvercrest Asset Management Group Inc. (NASDAQ:SAMG) is a favorite amongst institutional investors who own 64%

Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

Kinnate Biopharma, Madrigal Pharma, and More Stocks See Action From Activist Investors

Niu Technologies (NASDAQ:NIU) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Niu Technologies (NASDAQ:NIU) Q3 2023 Earnings Call Transcript

Share on Social Networks: